Cellectis S.A. (EPA:ALCLS)
France · Delayed Price · Currency is EUR 2.634
-0.104 (-3.80%)
Sep 11, 2026, 5:35 PM CET
Cellectis Market Cap
Cellectis has a market cap or net worth of €191.49 million as of September 11, 2026. Its market cap has increased by 2.22% in one year.
Market Cap
191.49M
Enterprise Value
115.92M
Revenue
55.86M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.63
ChartMarket Cap Chart
Since February 7, 2007, Cellectis's market cap has increased from 100.59M to 191.49M, an increase of 90.35%. That is a compound annual growth rate of 3.34%.
| Date | Market Cap | % Change |
|---|---|---|
| Sep 11, 2026 | 191.49M | -36.89% |
| Dec 31, 2025 | 303.40M | 158.68% |
| Dec 31, 2024 | 117.29M | -40.86% |
| Dec 29, 2023 | 198.32M | 118.98% |
| Dec 30, 2022 | 90.57M | -73.23% |
| Dec 31, 2021 | 338.35M | -67.37% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Genfit | 651.32M |
| DBV Technologies | 620.83M |
| Valneva SE | 547.70M |
| Valerio Therapeutics Société anonyme | 344.62M |
| Transgene | 241.29M |
| Innate Pharma | 149.15M |
| Sensorion | 117.36M |
| ABIONYX Pharma | 77.90M |